United Therapeutics Corporation (UTHR) Earnings History
Annual and quarterly earnings data from 1998 to 2025
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 87.9% | 46.9% | 41.9% |
| 2024 | 89.2% | 47.9% | 41.5% |
| 2023 | 88.9% | 50.9% | 42.3% |
| 2022 | 92.4% | 50.6% | 37.6% |
| 2021 | 92.7% | 33.0% | 28.2% |
Download Data
Export UTHR earnings history in CSV or JSON format
Free sign-in required to download data
United Therapeutics Corporation (UTHR) Earnings Overview
As of February 28, 2026, United Therapeutics Corporation (UTHR) reported trailing twelve-month net income of $1.33B, reflecting +0.1% year-over-year growth. The company earned $27.86 per diluted share over the past four quarters, with a net profit margin of 0.4%.
Looking at the long-term picture, UTHR's 5-year EPS compound annual growth rate (CAGR) stands at +19.3%, indicating exceptional earnings growth. The company achieved its highest annual net income of $1.33B in fiscal 2025, representing a new all-time high.
United Therapeutics Corporation maintains positive profitability with a gross margin of 0.9%, operating margin of 0.5%, and net margin of 0.4%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including ZLAB (-$176M net income, -0.4% margin), AMRN (-$86M net income, -0.4% margin), ALKS ($242M net income, 0.2% margin), UTHR has outperformed on profitability metrics. Compare UTHR vs ZLAB →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
28 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $1.33B | +11.7% | $1.49B | $27.86 | 41.9% | 46.9% |
| 2024 | $1.20B | +21.4% | $1.38B | $24.64 | 41.5% | 47.9% |
| 2023 | $985M | +35.4% | $1.18B | $19.81 | 42.3% | 50.9% |
| 2022 | $727M | +52.9% | $980M | $15.00 | 37.6% | 50.6% |
| 2021 | $476M | -7.6% | $556M | $10.06 | 28.2% | 33.0% |
| 2020 | $515M | +592.6% | $594M | $11.54 | 34.7% | 40.0% |
| 2019 | -$105M | -117.7% | -$188M | $-2.39 | -7.2% | -12.9% |
| 2018 | $589M | +41.0% | $805M | $13.39 | 36.2% | 49.5% |
| 2017 | $418M | -41.4% | $815M | $9.31 | 24.2% | 47.2% |
| 2016 | $714M | +9.5% | $1.06B | $15.25 | 44.6% | 66.4% |
See UTHR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs UTHR Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare UTHR vs AGIO
See how UTHR stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is UTHR growing earnings?
UTHR EPS of $27.86 reflects slowing growth at +0.1%, below the 5-year CAGR of +19.3%. TTM net income is $1.3B. Expansion rate has moderated.
What are UTHR's profit margins?
United Therapeutics Corporation net margin is +0.4%, with operating margin at +0.5%. Below-average margins reflect competitive or cost pressures.
How consistent are UTHR's earnings?
UTHR earnings data spans 1998-2025. The current earnings trend is +0.1% YoY. Historical data enables comparison across business cycles.